Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy

Alfonso Quintás-Cardama, Hagop Kantarjian, Guillermo Garcia-Manero, Susan O'Brien, Stefan Faderl, Zeev Estrov, Francis Giles, Anthony Murgo, Nakia Ladie, Srdan Verstovsek, Jorge Cortes

Research output: Contribution to journalArticlepeer-review

120 Scopus citations


BACKGROUND. Homoharringtonine (HHT) is a cephalotaxus alkaloid that inhibits the synthesis of proteins leading to apoptosis. Intravenous HHT has demonstrated activity in patients with chronic myeloid leukemia (CML) after failure with interferon. METHODS. A Phase I study was completed of subcutaneous (s.c.) HHT in patients with CML in accelerated or blast phases and demonstrated efficacy and good tolerance at the same doses used by intravenous (i.v.) administration. The maximal tolerated dose (MTD) was 1.25 mg/m2 s.c. twice daily. The cohort was then expanded to treated at the MTD to include patients in late chronic phase CML after imatinib failure. Therapy consisted of an i.v. loading dose of HHT 2.5 mg/m2 over 24 hours, followed by 1.25 mg/m2 s.c. twice daily for 14 days every 28 days until remission, then for 7 days every 28 days. Six patients (median age, 53 years) who had failed imatinib were treated and 5 were evaluable. Patients received a median of 4.5 courses of s.c. HHT. RESULTS. Complete hematologic remission was obtained in all 5 evaluable patients and 3 had cytogenetic (CG) responses: 1 complete and 2 minor. The 2 patients with BCR-ABL kinase domain mutations at the start of therapy with HHT had a CG response and in both instances the mutations became undetectable. All patients developed myelosuppression and 3 had their HHT dose reduced due to prolonged neutropenia. Nonhematologic toxicity was mild and manageable. CONCLUSIONS. Subcutaneous HHT is well tolerated and may have clinical activity in patients with CML after imatinib failure.

Original languageEnglish (US)
Pages (from-to)248-255
Number of pages8
Issue number2
StatePublished - Jan 15 2007
Externally publishedYes


  • ABL mutations
  • Chronic myelogenous leukemia
  • Homoharringtonine
  • Imatinib

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy'. Together they form a unique fingerprint.

Cite this